Skip to main content

Table 1 Baseline characteristics of the newly diagnosed HCC patients, 2002-2009 (n = 73,918)

From: Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database

Variables Male Female Total
(n = 52,860) (n = 21,058) (n = 73,918)
Age
 <50 9,830(18.6%) 1,613(7.7%) 11,443(15.5%)
 50–79 38,783(73.4%) 16,486(78.3%) 55,269(74.8%)
 ≥80 4,247(8.0%) 2,959(14.1%) 7,206(9.7%)
The incidence rate/year of HCC
 2002 6,122(11.6%) 2,359(11.2%) 8,481(11.5%)
 2003 6,110(11.6%) 2,331(11.1%) 8,441(11.4%)
 2004 6,346(12.0%) 2,465(11.7%) 8,811(11.9%)
 2005 6,570(12.4%) 2,495(11.8%) 9,065(12.3%)
 2006 6,528(12.3%) 2,569(12.2%) 9,097(12.3%)
 2007 6,922(13.1%) 2,723(12.9%) 9,645(13.0%)
 2008 7,100(13.4%) 3,013(14.3%) 10,113(13.7%)
 2009 7,162(13.5%) 3,103(14.7%) 10,265(13.9%)
Co-morbidities
 Chronic liver disease/cirrhosis (ICD9: 573 &571) 46,866(63.4%) 19,071(25.8%) 65,937(89.2%)
 Viral hepatitis (ICD9:070) 37,928(51.3%) 15,445(20.9%) 53,373(72.2%)
CHM prescribed (single or formula)
 2 years before HCC diagnosis 11,576(21.9%) 5,797(27.5%) 17,373(23.5%)
 2 years after HCC diagnosis 8,711(16.5%) 4,382(20.8%) 13,093(17.7%)
Single Chinese herbs prescribed
 2 years before HCC diagnosis 9,771(18.5%) 4,979(23.6%) 14,750(20.0%)
 2 years after HCC diagnosis 7,521(14.2%) 3,813(18.1%) 11,334(15.3%)
Chinese herbal formula prescribed
 2 years before HCC diagnosis 11,238(21.3%) 5,649(26.8%) 16,887(22.8%)
 2 years after HCC diagnosis 8,425(15.9%) 4,251(20.2%) 12,676(17.1%)